Frits Thaulow - "Winter at the River Simoa" (1883)

预约了深圳国际美术馆丨SIMOA七大展览启幕。有深圳的小伙伴可以偶遇一下 #深圳

Denial is not a River in Egypt 🔬 Study 1: The MEGALONG Study (Dr. Morgane Bomsel, Cochin Institute, Paris) The Target Tissue: Bone Marrow (Megakaryocytes) and Blood Platelets. The Breakthrough Findings: Dr. Bomsel’s team discovered that SARS-CoV-2 builds a replicating, infectious viral reservoir deep inside megakaryocytes—the large progenitor cells in the bone marrow that manufacture our blood platelets. The Mechanism: Because the root factory (the megakaryocyte) is chronically infected, it continuously seeds the bloodstream with viral loaded, metabolically altered platelets containing active viral RNA. This chronic infection inside our blood cells damages their energy production, alters serotonin storage, and triggers persistent platelet micro-aggregates. The Takeaway: This study is an absolute game-changer. It proves the virus isn't just floating around as dead fragments; it has hijacked the cellular factories of our blood production system, forcing them to pump out structurally dysfunctional, micro-clotting platelets month after month, year after year. 🔬 Study 2: The Harvard/Brigham Cohort Study (Dr. David Walt, et al.) The Target Tissue: The Gastrointestinal Tract and Vascular Endothelium. The Breakthrough Findings: Dr. Walt’s team used ultra-sensitive Simoa (Single Molecule Array) technology to scan the blood of LC patients. They found active, circulating SC2 Spike Protein, S1 subunit, and Nucleocapsid protein in the blood of LC patients up to 12 months post-infection. The Mechanism: Dead viral fragments or transcripted tissue scars would be cleared by the liver and kidneys within weeks. The continuous, steady leaking of full spike proteins into the bloodstream over a year later proves that a hidden tissue reservoir (primarily located in the deep lining of the gut) is actively and continuously manufacturing these viral proteins. The Takeaway: These circulating antigens act as a persistent, daily irritant to the immune system. The immune system never gets to reset, which is precisely why it continuously produces autoantibodies. The autoantibodies exist because the persistent spike protein is constantly waving a red flag at the immune system. 🔬 Study 3: The NIH/NCI Tissue Autopsy Study (Dr. Daniel Chertow, et al.) The Target Tissue: Comprehensive Multi-Organ Tissue (Brain, Heart, Nerves, Endothelium). The Breakthrough Findings: This was a meticulous NIH autopsy study of individuals who died with or after SARS-CoV-2 infection. The researchers mapped the exact physical presence of viral RNA throughout the human body. They proved that SARS-CoV-2 spreads systemically beyond the respiratory tract and persists in the brain, meninges, cardiovascular tissues, and peripheral nerves for at least 230 days post-infection. The Mechanism: They specifically isolated droplet digital PCR-validated viral RNA in deep tissues, demonstrating that the virus survives in non-respiratory cells long after it becomes completely undetectable on a standard nasal swab or plasma viral load test. The Takeaway: This completely shatters the idea that "we don't know if the virus is there." The virus has been physically imaged, mapped, and extracted from the deep tissues of the central nervous system and vascular walls. It proves that a negative nasal swab means absolutely nothing regarding what is happening inside your deep tissues. We all need to stop with this denial. It's literally killing us. When you clear the autoantibodies (actually immune antibody complexes) the replicating virus still replicates and cause signs and symptoms. And makes more antibody immune complexes (autoantibodies👎) I wish this wasn't the case but I am not an optimist or a pessimist. I am a realist.

遺伝性トランスサイレチンアミロイドーシスの血清NfL値はELISA法でもSIMOAと同等の制度で検出可能であり、有症状患者のNfL値は、無症状のキャリアと比較して統計的に有意に高い。臨床応用に期待です。frontiersin.org/journals/neu…

This week, we would like to introduce our customer's research that highlights the therapeutic potential of targeting the miR-485-3p/PGC-1α pathway in amyotrophic lateral sclerosis (ALS). Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis doi.org/10.3390/ijms27020615 Using ASO-loaded nanoparticles to inhibit miR-485-3p, the researchers observed improvements in mitochondrial function, reduced neuroinflammation, reservation of motor neurons, and decreased serum NfL levels. JS Link participated in this study through NfL ELISA analysis, providing quantitative measurements of neurofilament light chain levels for evaluation of the therapeutic approach in the mouse model. If you're also interested in proteomics analyses like this, let's discuss about your next research goals and needs: 📧 info@jslink.co.kr 🔗 jslinkseqlab.com #JSLinkSequencingLab #Proteomics #SIMOA #Quanterix #ALS #Sequencing #CertifiedServiceProvider

Recently opened on May 30, the Shenzhen International Museum of Art (SIMoA) is a world-class venue spanning nearly 50,000㎡ and launches with seven major exhibitions, offering a journey across millennia and continents in a single visit.

Across centuries, they endured. Now, they return.🏺 Join Shenzhen Culture and Tourism Ambassador DonLee as he explores "Return of National Treasures: The Bronze Animal Heads and the Memories of Ancient China" at the newly opened Shenzhen International Museum of Art (SIMoA).

Campanha Junho Vermelho e Semana Municipal de Doação de Plaquetas são celebradas em sessão solene. Iniciativa do vereador Fábio Simoa destacou a importância da doação de sangue e de plaquetas e homenageou doadores e colaboradores da Colsan. camarasorocaba.sp.gov.br/new…

En todellakaan tiedä, miksi Simo Juhani Frangén erosi Rosasta, mutta ilmeisesti joku syy on taustalla ollut. Itse olen luullut häntä ihan fiksuksi, siis Simoa ja varmaan onkin.

A campanha “Junho Vermelho”, de incentivo à doação de sangue e que engloba a Semana de Doação de Plaquetas, será comemorada em sessão solene da Câmara de Sorocaba, nesta terça-feira, 9, às 19 horas, por iniciativa do vereador Fábio Simoa (Republicanos). camarasorocaba.sp.gov.br/new…